FINWIRES · TerminalLIVE
FINWIRES

Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%

By

Nyrada (ASX:NYR) said its Xolatryp drug candidate provided significant protection to cardiac function against progressive doxorubicin-induced cardiotoxicity in a preclinical study, according to a Friday filing with the Australian bourse.

Doxorubicin is an anthracycline drug widely used as a first-line treatment for both solid and metastatic tumors, and is considered a "backbone drug" in oncology, the company said.

Doxorubicin treatment weakened the heart's ability to pump and empty blood effectively, and Xolatryp delivered benefits across four key measures of heart performance that were negatively impacted by doxorubicin, Nyrada said.

The magnitude of functional protection was comparable to dexrazoxane, which is the only approved cardioprotective agent, per the filing.

Nyrada said it will assess the design and feasibility of a potential phase 1b clinical trial of Xolatryp in the oncology setting.

The company's share gained 5% in recent Friday trade.

Related Articles

Asia

Fitch Keeps Petrovietnam Refining and Petrochemical's Rating at BB+, Outlook Stable

Fitch Ratings affirmed Petrovietnam Refining and Petrochemical's (HOSE:BSR) long-term issuer default rating at BB+, with a stable outlook.Fitch said the company's standalone credit profile of bb- reflects its strong market position and robust financial profile, partly offset by the small scale and below-average complexity of its Dung Quat refinery.The agency expects the company's refinery upgrade and expansion to raise capacity by 15% to 171,000 barrels per day.Fitch expects Petrovietnam Refining and Petrochemical to remain in a net cash position over the next two to three years despite rising capex during construction.The rating could be downgraded if PVN's rating falls or its incentives to support BSR weaken, while an upgrade would depend on a higher PVN rating with support incentives intact.

HOSE:BSR
Asia

Kingsoft Office Software H1 Profit Up 237%, Revenue Climbs 25%

Beijing Kingsoft Office Software (SHA:688111) posted first-half attributable net profit of 2.52 billion yuan, up 237% from 747.2 million yuan the previous year.Earnings per share rose to 5.41 yuan from 1.61 yuan, according to a Thursday filing with the Shanghai bourse.Revenue climbed 25% year over year to 3.31 billion yuan from 2.66 billion yuan.

SHA:688111
Asia

Bank of Ningbo's H1 Profit, Revenue Rise 12%; Shares Up 3%

Bank of Ningbo's (SHE:002142) net profit attributable to shareholders in the first half rose 12% to 16.6 billion yuan from 14.8 billion yuan a year earlier, according to a Shenzhen bourse filing on Thursday.Earnings per share increased year on year to 2.51 yuan from 2.24 yuan.Operating revenue also climbed 12% to 41.5 billion yuan from 37.2 billion yuan in the prior year.The lender said it will distribute a cash dividend of 4 yuan for every ten shares to registered shareholders.The company's shares rose 3% during the morning trade.

SHE:002142